Near-infrared spectral tomography for predicting residual cancer burden during early stage neoadjuvant chemotherapy for breast cancer.
Cao XuKristen E MullerMary D ChamberlinJiang GuiPeter A KaufmanGary N SchwartzRoberta M DiFlorio-AlexanderBrian W PogueKeith D PaulsenShudong JiangPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
NIRST holds promise as a potential clinical tool that can be seamlessly integrated into existing clinical workflow within the infusion suite. By providing early assessment of RCB, NIRST has potential to improve breast cancer patient management strategies.
Keyphrases
- neoadjuvant chemotherapy
- early stage
- sentinel lymph node
- locally advanced
- lymph node
- low dose
- case report
- human health
- squamous cell carcinoma
- magnetic resonance imaging
- papillary thyroid
- risk factors
- squamous cell
- childhood cancer
- machine learning
- electronic health record
- risk assessment
- magnetic resonance
- artificial intelligence
- deep learning
- clinical evaluation